Coya Therapeutics is a clinical-stage biotechnology company developing proprietary therapies that enhance regulatory T cell (Treg) function to treat neurodegenerative, autoimmune, and metabolic diseases. Their multi-modality approach includes biologics and cell therapies, with demonstrated proof of concept in conditions such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s disease.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurodegenerative, autoimmune, and metabolic diseases lack effective treatments that address the underlying immune dysregulation. Current therapies often provide symptomatic relief but fail to restore the balance of the immune system, particularly the function of regulatory T cells (Tregs). This can lead to disease progression and limited long-term benefits for patients.
Solution
Coya Therapeutics is developing a multi-modality platform of Treg-enhancing therapies, including biologics, cell therapies, and exosomes, to address immune dysregulation in neurodegenerative, autoimmune, and metabolic diseases. Their approach aims to restore immune homeostasis by enhancing the function of Tregs, which play a critical role in suppressing inflammation and maintaining immune tolerance. Coya's lead programs focus on enhancing Treg activity through various mechanisms, such as low-dose interleukin-2 (IL-2) and CTLA4-Ig combinations, to improve clinical outcomes in diseases like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The company's pipeline includes both autologous and allogeneic Treg-based therapies, as well as Treg-derived exosomes, offering a range of options to modulate the immune system and potentially halt or reverse disease progression.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases like ALS and Alzheimer's, as well as individuals with autoimmune and metabolic disorders characterized by immune dysregulation.
Features
- COYA 101: Autologous Treg cell therapy to restore immune balance.
- COYA 201: Allogeneic Treg-derived exosomes for targeted immune modulation.
- COYA 301: Treg-enhancing biologics designed to promote Treg function.
- COYA 302: Treg-enhancing biologics, a second molecule designed to promote Treg function.
- COYA 303: GLP-1/LD IL-2 combination biologic demonstrating synergistic enhancement of Treg function and protection against Treg apoptosis.
- Investigational low-dose Interleukin-2 (IL-2) to stimulate Treg proliferation and activity.
- CTLA4-Ig combination treatments to enhance Treg suppressive function.